<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>relapsed refractory T-cell lymphoma &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/relapsed-refractory-t-cell-lymphoma/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 06 Sep 2025 10:09:03 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>relapsed refractory T-cell lymphoma &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Novel Drug Combination Shows Promise in Treating T-Cell Lymphoma</title>
		<link>https://bioengineer.org/novel-drug-combination-shows-promise-in-treating-t-cell-lymphoma/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 01 Jul 2025 16:57:17 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[duvelisib-romidepsin combination]]></category>
		<category><![CDATA[PI3K HDAC inhibition]]></category>
		<category><![CDATA[real-world lymphoma treatment]]></category>
		<category><![CDATA[relapsed refractory T-cell lymphoma]]></category>
		<category><![CDATA[stem cell transplantation bridge]]></category>
		<guid isPermaLink="false">https://bioengineer.org/novel-drug-combination-shows-promise-in-treating-t-cell-lymphoma/</guid>

					<description><![CDATA[Relapsed and refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) present some of the most formidable challenges within hematologic malignancies. These aggressive forms of lymphoma are notorious for their resistance to conventional therapies, often leaving patients with limited treatment options and poor prognoses. The clinical management of such diseases, therefore, demands innovative therapeutic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">250923</post-id>	</item>
	</channel>
</rss>
